NRX Pharmaceuticals (FRA:B1Q) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B1Q NRX Pharmaceuticals Inc FRA:B1Q
33 GF Score
Price €3.79
! 4 Warning Signs
View Full Analysis

What is NRX Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:B1Q
33GF Score
NRX Pharmaceuticals Inc FRA:B1Q
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NRX Pharmaceuticals Business Description

Other Exchanges NRXP:USA
Address 1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
33GF Score

Get the complete analysis for FRA:B1Q

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.79
Price